CJ CheilJedang to expand L-Arginine and L-Citrulline production in Indonesia
13 Apr 2018 --- CJ CheilJedang is making plans to build a production line, dedicated to the creation of L-Arginine and L-Citrulline at its Jombang plant, in Indonesia, which will start operating in 2019. The company currently produces nucleic acid, MSG, arginine and histidine at the Jombang plant. Meanwhile, the company is also planning to improve the productivity of L-Citrulline at its outpost, Ningbo production plant in China.
L-Citrulline, previously manufactured on a separate production line, will be produced on a unified production line of L-Arginine and L-Citrulline at the plant. This will increase the competitiveness and also enhance the quality of the products through tightened quality control. Moreover, by producing L-Citrulline simultaneously in both China and Indonesia, the company will be able to develop multi-plant production. As a result, CJ CheilJedang is expected to acquire supply stability by minimizing the risk arising from environmental regulation in China and thus, ensure a stable supply of products to customers.
L-Arginine is an amino acid that promotes vasodilation through generating Nitric Oxide; L-Citruline, generated through UREA Cycle with L-Arginine and ornithine, keeps arginine concentration in your body higher and longer. Both amino acids are used diversely in both sports nutrition and nutraceutical areas.
Leveraging the positive health effect of amino acids in disease prevention and blood circulation, CJ CheilJedang is looking to expand its business into beverages and processed foods.
AMINATURE, the CJ CheilJedang’s food grade amino acid brand, is claimed to differentiate itself from other amino acid brands that use hair, pig bristle or duck feathers, for example, by producing its products through CJ’s Onlyone fermentation method.
This feature is provided by Nutrition Insight’s sister website, Food Ingredients First.
To contact our editorial team please email us at editorial@cnsmedia.com
Subscribe now to receive the latest news directly into your inbox.